Purinergic signaling pathways in endocrine system.
Bethesda, United States. In Auton Neurosci, 25 May 2015
This article provides a review of purinergic signaling pathways in the hypothalamic magnocellular neurosecretory cells and neurohypophysis, hypothalamic parvocellular neuroendocrine system, adenohypophysis, and effector glands organized in five axes: hypothalamic-pituitary-gonadal, hypothalamic-pituitary-thyroid, hypothalamic-pituitary-adrenal, hypothalamic-pituitary-growth hormone, and hypothalamic-pituitary-prolactin.
Endocrine and neuroendocrine regulation of fathering behavior in birds.
Wooster, United States. In Horm Behav, 17 May 2015
This review focuses on proximate mechanisms of paternal care in birds, with an emphasis on specific hormones that vary predictably and/or unpredictably during the parental phase in both captive and wild birds: prolactin and progesterone are generally assumed to enhance paternal care, whereas testosterone and corticosterone are commonly-though not always correctly-assumed to inhibit paternal care.
Hypogonadism and renal failure: An update.
Boston, United States. In Indian J Urol, 30 Apr 2015
Renal failure can lead to decreased luteinizing hormone production and decreased prolactin clearance that could impair testosterone production.
Bisphenol A and phthalate endocrine disruption of parental and social behaviors.
Columbia, United States. In Front Neurosci, Dec 2014
These behavioral disturbances may originate by altering the fetal or adult gonadal production of testosterone or estrogen, expression of ESR1, ESR2, and AR in the brain regions governing these behaviors, neuropeptide/protein hormone (oxytocin, vasopressin, and prolactin) and their cognate neural receptors, and/or through epimutations.
Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer.
More papers using
Boston, United States. In J Clin Oncol, Nov 2014
Therefore, we evaluated whether inclusion of plasma estradiol, estrone, estrone sulfate, testosterone, dehydroepiandrosterone sulfate, prolactin, and sex hormone-binding globulin (SHBG) improved risk prediction for postmenopausal invasive breast cancer (n = 437 patient cases and n = 775 controls not using postmenopausal hormones) in the Nurses' Health Study.